Factors Associated with Mortality Among Hospitalized Adults with COVID-19 Pneumonia at a Private Tertiary Hospital in Tanzania: A Retrospective Cohort Study by Kassam, Nadeem et al.
eCommons@AKU 
Internal Medicine, East Africa Medical College, East Africa 
8-2021 
Factors Associated with Mortality Among Hospitalized Adults 
with COVID-19 Pneumonia at a Private Tertiary Hospital in 






See next page for additional authors 
Follow this and additional works at: https://ecommons.aku.edu/eastafrica_fhs_mc_intern_med 
 Part of the Internal Medicine Commons 
Authors 
Nadeem Kassam, Eric Aghan, Omar Aziz, Hanifa Mbithe, Kamran Hamid, Reena Shah, Salim Surani, 
James Orwa, and Samina Somji 
O R I G I N A L  R E S E A R C H
Factors Associated with Mortality Among 
Hospitalized Adults with COVID-19 Pneumonia at 
a Private Tertiary Hospital in Tanzania: 
A Retrospective Cohort Study









1Internal Medicine, The Aga Khan 
Hospital, Dar es Salaam, Tanzania & Aga 
Khan University, Medical College, Dar-es- 
Salaam, Tanzania; 2Family Medicine, The 
Aga Khan Hospital, Dar es Salaam, 
Tanzania & Aga Khan University, Medical 
College, East Africa, Dar-es-Salaam, 
Tanzania; 3Infectious Disease & Internal 
Medicine, The Aga Khan University, 
Medical College, Nairobi, Kenya; 
4Pulmonology & Internal Medicine, Texas 
a&m University, Texas A&M College 
Station, TX, USA; 5Population Health, 
Aga Khan University, Medical College, 
East Africa, Nairobi, Kenya 
Background: The emergence of the novel coronavirus disease 2019 (COVID-19) has 
caused millions of deaths worldwide. There has been paucity of data for hospitalized 
African patients suffering from COVID-19. This study aimed to identify factors associated 
with in-hospital mortality in patients suffering from COVID-19 in Tanzania.
Methods: This was a single center, retrospective, observational cohort study in adult patients 
hospitalized with confirmed COVID-19 infection. Demographics, clinical pattern, laboratory 
and radiological investigations associated with increased odds of mortality were analyzed.
Results: Of the 157 patients, 107 (68.1%) patients survived and 50 (31.8%) died. Mortality 
was highest in patients suffering with severe (26%) and critical (68%) forms of the disease. 
The median age of the cohort was 52 years (IQR 42–61), majority of patients were male 
(86%) and of African origin (46%), who presented with fever (69%), cough (62%) and 
difficulty in breathing (43%). Factors that were associated with mortality among our cohort 
were advanced age (OR 1.07, 95% CI 1.03–1.11), being overweight and obese (OR 9.44, 
95% CI 2.71–41.0), suffering with severe form of the disease (OR 4.77, 95% CI 1.18–25.0) 
and being admitted to the HDU and ICU (OR 6.68, 95% CI 2.06–24.6).
Conclusion: The overall in-hospital mortality was 31.8%. Older age, obesity, the severe 
form of the disease and admission to the ICU and HDU were major risk factors associated 
with in-hospital mortality.
Keywords: COVID-19, factors, hospital, mortality, Tanzania
Introduction
Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 first emerged in 
Hubei Province, China in December 2019. Since then, not only has COVID-19 
been considered a health emergency of international concern1 but it has also been 
declared a global pandemic.1 As of 9th July, 2021, the World Health Organization 
(WHO) officially confirmed over 185 million cases of COVID-19 globally with 
4 million deaths. Tanzania reported its first case on 16th March 2020.2 Even 
though most African countries have a fragile health system, the Case Fatality Rate 
(CFR) for COVID-19 in Africa is surprisingly lower than the global trend.3 Low 
testing rates, a younger population, humid temperatures and possibility of 
a preexisting immunity are some of the postulated factors associated with this 
difference.3
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Although the SARS-CoV-2 virus predominantly targets 
the respiratory system,4 its associated mortality involves 
multiple organ systems.4 An increasing understanding of 
the disease over the course of the pandemic has led to reduc-
tion in in-hospital mortality rates, especially in well- 
resourced and high-income countries.5–7 In contrast, in- 
hospital mortality remains comparatively high in Africa. 
This has been attributed to the burden of underlying comor-
bidities and resource deficits.8 Reports globally have indi-
cated that increasing age,9–11 comorbidities (cardiovascular 
disease, diabetes)9,12,13 and obesity14,15 are all associated 
with adverse outcomes. In addition, certain demographic 
characteristics10–12,16 and laboratory parameters17–19 have 
also been associated with the severe form of COVID-19 
and increased mortality.
In Tanzania, the population characteristics skew 
towards the younger age range and a lower life expectancy 
compared to higher-income countries. Despite the alarm-
ing growing numbers of non-communicable diseases 
(NCD),20 communicable diseases such as human immuno-
deficiency virus (HIV), tuberculosis, malaria and other 
neglected infectious diseases are still highly prevalent in 
the population. The objective of the present study was to 
describe clinical features and identify risk factors asso-
ciated with mortality among patients hospitalized with 
COVID-19 in Tanzania.
Methodology
Study Design and Participants
This was a retrospective cohort study of adults aged 18 
years and above admitted to the COVID-19 isolation unit 
between 29th March and 31st July 2020. We enrolled 
eligible patients that were hospitalized with confirmed 
COVID-19 via a positive SARS-CoV-2 RT-PCR and had 
a final outcome (either death or discharge). The criteria for 
discharge was maintenance of oxygen saturation at rest or 
above 94% on room air, respiratory rate less than 24 
breaths/min and absence of fevers over a 24-hour period.
Study Location
The study was conducted at the COVID-19 isolation unit 
of the Aga Khan Hospital, Dar es Salaam, Tanzania. The 
Aga Khan Hospital, Dar es Salaam is the only Joint 
Commission International (JCI) accredited hospital in the 
country. The COVID-19 isolation unit is housed in 
a building separate from other patients and comprises the 
general isolation ward and the COVID-19 Critical Care 
Unit (CCU). The CCU is split into the intensive care unit 
(ICU) and the high dependency unit (HDU). The general 
isolation ward consisted of two separate wards (one for 
suspect cases and one for confirmed positive PCR patients) 
located on two separate floors with 25 beds each. The 
COVID-19 CCU has an eight-bed ICU and twelve-bed 
HDU. The suspect and confirmed isolation ward is over-
seen by a clinical team that is composed of specialists 
from the department of internal medicine, paediatrics, as 
well as residents, medical officers, and interns. Both the 
HDU and ICU are managed by a multidisciplinary team, 
which includes a full-time critical care specialist, primary 
physician, internal medicine resident, medical officer, phy-
siotherapist and dietician. The ICU is able to provide both 
invasive and non-invasive mechanical ventilation, invasive 
hemodynamic monitoring, and inotropic support. The 
HDU serves as a step-down unit for the ICU and houses 
patients who are critically ill requiring high-flow oxygen. 
Patients requiring hemodialysis are transferred to 
a separate designated dialysis unit within the isolation 
unit. The ICU and HDU have round-the-clock coverage 
with an anesthesiologist and a team of medical officers 
from various specialties such as internal medicine, 
anesthesia, and emergency medicine. The nurse-to-patient 
ratio for ICU and HDU was 1:1 and 1:4, respectively.
Data Collection
We obtained medical records and compiled data for adult 
patients aged 18 years and above with laboratory confirmed 
COVID-19 as tested by the National Public Health 
Laboratory, between 29th March and 31st July 2020. The 
admission register was used to identify patients; their files 
both electronic and paper-based were retrieved from medical 
records. Patient demographics, clinical and laboratory data as 
well as radiological findings and outcomes were obtained. 
Data were collected by research assistants who had experi-
ence working in the COVID-19 isolation unit. Extracted data 
were independently verified by the primary investigator for 
accuracy and completeness. We categorized race into three 
main categories: African, South Asians (Indians and 
Pakistanis) and Chinese. The rest were grouped under 
“Others”. Patients’ initial radiographs, done on admission 
to the hospital, were classified broadly into four main groups: 
local patchy shadowing, bilateral patchy shadowing, inter-
stitial abnormalities and ground glass opacification. Patient’s 
clinical status21 and Body Mass Index (BMI) were classified 
according to WHO classification.22
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Laboratory Procedures and Treatment 
Protocol
Nasal and oropharyngeal swab samples for patients admitted 
were collected by trained laboratory technicians and placed 
in sterile viral transport media tubes. These were delivered 
to the National Public Health Laboratory (NPHL) strictly 
following government and WHO protocols for collection, 
storage and transport. At NHPL, the samples were tested for 
SARS-CoV-2 using reverse transcription-polymerase chain 
reaction (RT-PCR). Results were mailed back to the hospital 
through a central and local public health body reporting 
mechanism. A confirmed case of COVID-19 was defined 
as positive on RT-PCR assay of nasal and oropharyngeal 
swab specimens.
The standard institutional guideline for COVID-19 
patients was divided into two: (i) general management 
and (ii) COVID-19 specific therapy. General management 
included the guidance on the use of empiric treatment 
(intravenous (IV) Ceftriaxone 1000 mg twice daily or IV 
Piperacillin-Tazobactam 4500 mg thrice daily) for bacter-
ial co-infection, prevention and therapy of venous throm-
boembolism for all hospitalized patients, the use of IV 
paracetamol for fever, treatment of underlying conditions, 
protocols for chest physiotherapy, nutritional guidance and 
a note to avoid forms of medication given by nebulization 
to prevent aerosolization of viral particles. At the time of 
this study, the only COVID-19 specific therapy used was 
daily systemic corticosteroids either intravenous 
Dexamethasone 6 mg IV once daily or oral Prednisolone 
0.5mg/kg/day in two divided doses, but this was limited to 
those who required oxygen or who were critically ill. We 
encouraged all oxygen-dependent hospitalized patients to 
spend as much time as practical and safe in prone position. 
For patients requiring oxygen supplementation, we fol-
lowed recommendations from WHO which suggested 
titrating oxygen to target peripheral oxygen saturation 
(SpO2) of ≥94% with the lowest fraction of inspired oxy-
gen (FiO2). The decision to intubate was multifactorial and 
was dependent on clinical and gas exchange parameters.
Statistical Analysis
Demographic data were summarized using frequency 
tables and percentages, while continuous and categorical 
variables were presented as median (IQR) and n (%), 
respectively. A chi-square test/Fisher's exact test was 
used to identify the presence of a statistical significant 
difference between survivors and non-survivors. 
Statistical significant difference was set at a p-value of 
<0.05. To identify factors associated with mortality in 
hospitalized COVID-19 disease, logistic regression 
model was used. Variables significantly associated with 
disease severity at 5% level of significance in the univari-
ate analysis were considered in the multivariable model. In 
the final model, adjusted odds ratio (OR), p-value and 95% 
CI for OR were used to test significance and interpretation 
of results. Variables with p-value ≤0.05 were considered as 
major risk factors associated with mortality. All analyses 
were performed using STATA software version 15 
(College Station, TX).
Results
During the study period; 157 patients who tested positive 
for SARS-CoV-2 were included in the analysis of the 
study, out of which 107 (68.2%) survived, while 50 
(31.8%) died. Table 1 shows general and clinical charac-
teristics of the cohort and provides a comparison of survi-
vors to non-survivors. The median age of the cohort was 
52 years (IQR 42–61). The majority of the population 
were male (86%) and of African origin (46%). More 
than one comorbid condition per critically ill patient was 
recorded when present. The most common comorbid con-
dition amongst our cohort was diabetes mellitus (11%) and 
hypertension (7.6%). Most notably two-thirds of the 
cohort population was either overweight (30%) or obese 
(37%). The overall median length of stay was 6 days (IQR 
3–10). Higher percentage of mortality with statistical sig-
nificance (P < 0.05) was noted amongst males (78%), aged 
between 45 and 64 years (44%), those who were suffering 
from both diabetes mellitus as well as hypertension (30%) 
and those who were obese (62%).
Majority of our patients were symptomatic; the most 
common symptoms on admission were fever (69%), cough 
(62%) and difficulty in breathing (43%) as shown in 
Table 2. Vitals on admission were evaluated; the overall 
median respiratory and pulse rates were 24 breaths/min 
(IQR 20–30) and 98 beats/min (IQR 85–110), respectively. 
When survivors and non-survivors were compared, 
a higher percentage of mortality with statistical signifi-
cance (P < 0.05) was noted in those who presented with 
difficulty in breathing (54%). Additionally, a higher 
respiratory rate of 28 breaths/min (IQR 24–33) and pulse 
rate of 104 beats/min (IQR 90–120) was noted amongst 
non-survivors (P < 0.05). No statistically significant dif-
ference was noted when systolic and diastolic blood 
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pressures were compared amongst survivors and non- 
survivors.
More than half (67%) patients required oxygen supple-
mentation on admission as seen in Table 3 either via nasal 
prongs (16%), face mask (7.6%) or non-rebreather mask 
(39%). Six patients (3.8%) were intubated at accident's and 
emergency department prior to admission, of which five 
did not make it to hospital discharge. Normal chest X-ray 
on admission was only noted amongst 20 patients (15%), 
with the majority having radiological features suggestive 
of bilateral patchy shadowing (34%) or ground glass opa-
cities (24%). The bulk of the admissions was patients 
suffering from the severe (39%) and critical (29%) form 
of the disease. When survivors and non-survivors were 
compared, higher mortality rates were noted in those 
who required oxygen support via non-rebreather mask 
(66%), suffering with critical illness (68%) and those 
who required intensive care (40%).
Table 4, below illustrates initial laboratory parameters 
of our study population and provides a comparison of 
survivors to non-survivors. We observed a statistically sig-
nificant difference (P < 0.05) in initial laboratory findings 
between survivors and non-survivors. Non-survivors had 
a significantly higher median leukocyte count 10.4×109/L 
(IQR 6.3 −14.9), absolute neutrophil count 8.3×109/L 
(IQR 5.0–13.9) and an elevated C-reactive protein (CRP) 
207 mg/L (IQR 90–301). Likewise, higher levels of serum 
Lactate Dehydrogenase (LDH) 504 IU/L (IQR 412–728), 
Table 1 Demographic and Clinical Characteristics of Patients
Variable N Overall, N = 157a Patient Outcome p-valueb
Survivor, N = 107a Non-Survivors, N = 50a
Age 157 52 (42–61) 48 (37–57) 60 (49–69) <0.001
< 45 52 (33%) 44 (41%) 8 (16%)
45–64 71 (45%) 49 (46%) 22 (44%)
65–74 27 (17%) 11 (10%) 16 (32%)
>75 7 (4.5%) 3 (2.8%) 4 (8.0%)
Sex 157 0.049
Female 22 (14%) 11 (10%) 11 (22%)
Male 135 (86%) 96 (90%) 39 (78%)
Race 157 <0.001
African 72 (46%) 45 (42%) 27 (54%)
South Asians 53 (34%) 32 (30%) 21 (42%)
Chinese 9 (5%) 9 (8.4%) 0 (0%)
Others 23 (15%) 21 (9.6%) 2 (4.0%)
Comorbids 157
None 62 (39%) 58 (54%) 4 (8.0%) < 0.0001
DM 18 (11%) 15 (14%) 3 (6.0%) 0.1418
HTN 12 (7.6%) 9 (8.4%) 3 (6.0%) 0.5963
HIV 4 (2.5%) 1 (0.9%) 3 (6.0%) 0.0606
Asthma or COPD 9 (5.7%) 3 (2.8%) 6 (12%) 0.0209
DM & HTN 29 (18%) 14 (13%) 15 (30%) 0.0109
DM, HTN, and CKD 9 (5.7%) 6 (5.6%) 3 (6.0%) 0.9215
DM, HTN, and CAD 4 (2.5%) 0 (0%) 4 (8.0%) 0.0030
Others 10 (6.4%) 1 (0.9%) 9 (18%) < 0.0001
BMI 134 <0.001
Healthy weight 44 (33%) 39 (45%) 5 (10%)
Overweight 40 (30%) 27 (31%) 13 (27%)
Obese 50 (37%) 20 (23%) 30 (62%)
LOS (Days) 6 (3-10) 6 (4-11) 3 (1-7) <0.001
Notes: aMedian (IQR) or frequency (%) bWilcoxon rank sum test; Fisher’s exact test; Pearson’s Chi-squared test. 
Abbreviations: DM, diabetes mellitus; HTN, hypertension; CKD, chronic kidney disease; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; 
BMI, body mass index; LOS, length of stay; <, less than; >, more than.
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Table 2 Presenting Symptoms and Initial Vitals on Admission
Variable N Overall, N = 157a Patient Outcome p-valueb
Survivor, N = 107a Non-Survivors, N = 50a
Symptoms
Cough 157 97 (62%) 74 (69%) 23 (46%) 0.005
Fever 157 108 (69%) 75 (70%) 33 (66%) 0.61
Difficulty breathing 157 67 (43%) 40 (37%) 27 (54%) 0.050
Malaise 157 47 (29.9%) 46 (43%) 1 (2.0%) <0.001
Headache 157 17 (11%) 17 (16%) 0 (0%) 0.003
Gastrointestinal symptoms 157 13 (8.3%) 8 (7.5%) 5 (10%) 0.76
Others 157 9 (5.7%) 4 (3.7%) 5 (10%) 0.14
Vitals
Respiratory rate (breaths/min) 157 24 (20–30) 23 (19–26) 28 (24–33) <0.001
Systolic blood pressure (mmHg) 157 126 (117–140) 128 (120–140) 123 (109–140) 0.11
Diastolic blood pressure (mmHg) 157 80 (70–87) 80 (74–87) 78 (60–84) 0.073
SpO2 (%) 157 92 (88–96) 94 (90–96) 88 (78–93) <0.001
Heart rate (beats/min) 157 98 (85–110) 93 (84–105) 104 (90–120) <0.001
Notes: aMedian (IQR) or frequency (%), bWilcoxon rank sum test; Fisher’s exact test; Pearson’s Chi-squared test. 
Abbreviation: SpO2, oxygen saturation.
Table 3 Type of Initial Respiratory Support, Chest X-Ray Findings, Admitting Ward and Severity of the Disease on Admission
Variable N Overall, N = 157a Patient Outcome p-valueb
Survivor, N = 107a Non-Survivors, N = 50a
Initial support 157 <0.001
No support 52 (33%) 50 (47%) 2 (4.0%)
Nasal prongs 25 (16%) 22 (21%) 3 (6.0%)
Face mask 12 (7.6%) 5 (4.7%) 7 (14%)
Non-rebreather mask 62 (39%) 29 (27%) 33 (66%)
Intubated 6 (3.8%) 1 (0.9%) 5 (10%)
Chest x-ray 135 0.029
Normal 20 (15%) 19 (21%) 1 (2.2%)
Bilateral patchy shadowing 46 (34%) 26 (29%) 20 (43%)
Ground glass opacities 32 (24%) 19 (21%) 13 (28%)
Interstitial abnormalities 9 (6.7%) 5 (5.6%) 4 (8.7%)
Local patchy shadowing 12 (8.9%) 9 (10%) 3 (6.5%)
Others 16 (12%) 11 (12%) 5 (11%)
Admitted to 157 <0.001
General ward 99 (63%) 85 (79%) 14 (28%)
HDU 29 (18%) 13 (12%) 16 (32%)
ICU 29 (18%) 9 (8.4%) 20 (40%)
Severity 157 <0.001
Moderate 51 (32%) 48 (45%) 3 (6.0%)
Severe 61 (39%) 48 (45%) 13 (26%)
Critical 45 (29%) 11 (10%) 34 (68%)
Notes: aMedian (IQR) or frequency (%), bFisher’s exact test; Pearson’s Chi-squared test. 
Abbreviations: HDU, high dependency unit; ICU, intensive care unit.
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Table 4 Laboratory Parameters on Admission
Variable N Overall, N = 157a Patient Outcome p-valueb
Survivor, N = 107a Non-Survivors, N = 50a
WBC (109/L) 154 7.9 (5.7–10.8) 7.2 (5.4–9.4) 10.4 (6.3–14.9) <0.001
< 4 8 (5.2%) 6 (5.8%) 2 (4.0%)
4–10 98 (64%) 77 (74%) 21 (42%)
> 10 48 (31%) 21 (20%) 27 (54%)
ANC (109/L) 154 5.9 (3.8–9.2) 5.4 (3.5–8.0) 8.3 (5.0–13.9) <0.001
< 1.8 3 (1.9%) 3 (2.9%) 0 (0%)
1.8–6.3 81 (53%) 62 (60%) 19 (38%)
> 6.3 70 (45%) 39 (38%) 31 (62%)
ALC (109/L) 154 0.89 (0.65–1.45) 0.88 (0.65–1.37) 1.00 (0.67-1.63) 0.47
< 0.8 64 (42%) 44 (42%) 20 (40%)
0.8–1.0 20 (13%) 15 (14%) 5 (10%)
> 1.0 70 (45%) 45 (43%) 25 (50%)
CRP (mg/L) 151 134 (52–267) 109 (47–220) 207 (90–301) 0.004
< 50 37 (25%) 29 (28%) 8 (17%)
50–100 23 (15%) 18 (17%) 5 (10%)
100–200 37 (25%) 26 (25%) 11 (23%)
> 200 54 (36%) 30 (29%) 24 (50%)
LDH (IU/L) 139 446 (304–576) 392 (282–533) 504 (412–728) 0.002
≤ 225 16 (12%) 14 (15%) 2 (4.3%)
> 225 123 (88%) 79 (85%) 44 (96%)
D-dimer (mg/L) 134 0.68 (0.39–1.93) 0.58 (0.35–1.34) 1.44 (0.58–5.74) <0.001
< 0.5 46 (34%) 39 (41%) 7 (18%)
0.5–1.0 32 (24%) 21 (22%) 11 (28%)
> 1.0 56 (42%) 34 (36%) 22 (55%)
Ferritin (µg/L) 118 928 (525–1843) 960 (525–1905) 829 (563–1573) 0.79
Unknown 39 21 18
< 250 19 (16%) 14 (16%) 5 (16%)
250–500 10 (8.5%) 7 (8.1%) 3 (9.7%)
> 500 88 (75%) 65 (76%) 23 (74%)
INR 72 1.15 (1.10–1.34) 1.13 (1.07–1.27) 1.25 (1.15–1.64) 0.007
0–1 4 (5.6%) 3 (6.5%) 1 (3.8%)
1.0–1.5 56 (78%) 38 (83%) 18 (69%)
> 1.5 12 (17%) 5 (11%) 7 (27%)
BUN (mmol/L) 118 5.9 (3.9–9.9) 5.0 (3.3–7.6) 8.2 (4.8–12.4) <0.001
≤ 9.5 87 (74%) 60 (83%) 27 (59%)
> 9.5 31 (26%) 12 (17%) 19 (41%)
Creatinine (μmol/L) 127 85 (72–114) 82 (71–101) 95 (76–134) 0.040
≤ 104 88 (69%) 63 (79%) 25 (53%)
> 104 39 (31%) 17 (21%) 22 (47%)
AST (IU/L) 81 49 (29–83) 38 (25–66) 64 (42–99) 0.007
≤ 40 34 (42%) 27 (54%) 7 (23%)
> 40 47 (58%) 23 (46%) 24 (77%)
ALT (IU/L) 82 35 (22–65) 40 (22–67) 33 (22–54) 0.57
≤ 41 46 (56%) 25 (50%) 21 (66%)
> 41 36 (44%) 25 (50%) 11 (34%)
Notes: aMedian (IQR) or frequency (%) bWilcoxon rank sum test; Fisher’s exact test; Pearson’s Chi-squared test. 
Abbreviations: ANC, absolute neutrophil count; ALC, absolute lymphocyte count; CRP, C-reactive protein; LDH, lactate dehydrogenase; INR, international normalized 
ratio; BUN, blood urea nitrogen; AST, aspartate aminotransferase; ALT, alanine aminotransferase; <, less than; >, more than.
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D-dimer 1.44 mg/L (IQR 0.58–5.74) and deranged 
International Normalized Ratio (INR) 1.25 (IQR 1.15– 
1.64) were noted amongst the non-survivors (P < 0.05). 
Absolute lymphocyte counts and ferritin levels did not 
reveal any statistical significant difference when survivors 
and non-survivors were compared.
Table 5 illustrates the risk factors associated with increased 
risk of mortality. In the univariable analysis, the odds of in- 
hospital mortality were higher in advanced age, those suffering 
from diabetes mellitus, hypertension or both. Being over-
weight and obese, suffering with severe form of illness, requir-
ing oxygen supplementation on admission and being admitted 
to the ICU and HDU were other factors associated with 
increased odds of in-hospital mortality. In the multivariable 
logistic regression model, we found advanced age (OR 1.07, 
95% CI 1.03–1.11), overweight and obesity (OR 9.44, 95% CI 
2.71–41.0), severe form of the disease (OR 4.77, 95% CI 
1.18–25.0) and being admitted to the HDU and ICU (OR 
6.68, 95% CI 2.06–24.6) to be the primary factors associated 
with higher odds of in-hospital mortality.
Discussion
The in-hospital mortality amongst our cohort was 31.8%. 
Our study identified several risk factors associated with 
mortality amongst hospitalized patients with COVID-19 in 
a Tanzanian setting. The in-hospital mortality was lower 
compared to the average mortality reported in Africa8 but 
higher than the global average amongst hospitalized 
patients with COVID-19.23 Our study identified advanced 
age, overweight and obesity, severe form of the illness and 
Table 5 Factors Associated with Increased Odds of Mortality Among Patients Suffering with COVID-19
Variable Univariable Analysis Multivariable Analysis
OR 95% CI P-value OR 95% CI P-value
Age (years) 1.05 1.02–1.08 <0.001 1.07 1.03–1.11 0.001
Diabetes mellitus
No Ref
Yes 2.11 1.05–4.28 0.037
Hypertension
No Ref
Yes 2.87 1.39–5.96 0.004
Diabetes mellitus & hypertension
No Ref
Yes 4.07 1.84–9.23 <0.001 1.71 0.48–6.24 0.400
Comorbids
With Ref
Without 0.07 0.02–0.20 <0.001
BMI
Healthy weight Ref
Overweight & obese 7.14 2.78–22.2 <0.001 9.44 2.71–41.0 0.001
Severity
Non severe Ref
Severe 12.7 4.32–54.7 <0.001 4.77 1.18–25.0 0.039
Admitting ward
Isolation ward Ref
CCU (HDU & ICU) 9.94 4.68–22.2 <0.001 6.68 2.06–24.6 0.002
Initial oxygen support
No Ref
Yes 21.1 6.09–133.0 <0.001
D-dimer > 1 mg/L 1.34 1.13–1.59 <0.001
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admission to the CCU (HDU & ICU) as the main factors 
associated with higher odds of mortality.
Studies have shown adults are more likely to suffer with 
severe form of the disease. The median age of hospitalized 
patients with COVID-19 ranges from 49 to 56 years.4,24,25 
Our study findings are consistent with reports published 
globally and comparable to other studies done in 
Africa.8,26 Elderly and males have been found to be at an 
increased risk of mortality, this has been associated with the 
higher levels of angiotensin-converting enzyme 2 (ACE2), 
which is a cell surface receptor for SARS-CoV-2.27 
Nevertheless, our study did not find any association 
between gender and increased odds of mortality.
Our study also identified obesity to be significantly asso-
ciated with in-hospital mortality. Our findings are consistent 
with those done in the United States15,28 but contrary to study 
findings from ten different countries in Africa.8 We hypothe-
size the difference could be in part due to the large cohort of the 
foreign community which our center serves. The spectrum of 
COVID-19 ranges from mild to critical; however, most indi-
viduals suffer from mild form of the disease.9 In our cohort, 
more than half of the patients who died were admitted to the 
HDU and ICU, suffering from the critical form of illness. 
Similar reports of ICU mortality due to COVID-19 have 
been reported globally.29–31 It is unfortunate the limited 
scope of our study cannot identify the causes of high mortality 
in our ICU setting as there is no readily available data. 
However globally, acute respiratory distress syndrome 
(ARDS),10,12 cardiovascular,16,25,32 thromboembolic33,34 and 
neurologic complications35 have been reported as the main 
cause of mortality in ICU patients suffering with critical 
forms of COVID-19.
Our study results are concordant with reported risk 
factors of COVID-19 mortalities worldwide. Our study 
had several limitations. This was a single-center obser-
vational cohort study in a well-resourced private health-
care setting, thus limiting the generalizability of our 
results to public facilities. Lack of national guidelines 
at the time of the study hindered development, valida-
tion and application of appropriate clinical and radiolo-
gical scoring systems. Additionally, the retrospective 
study design restricted us from following up our patients 
after hospital discharge. Despite these limitations, the 
experience and the data analyzed have set a benchmark 
for more research in addressing areas of clinical 
improvement within Tanzania.
Conclusion
This is the first and the largest study done in Tanzania of 
hospitalized COVID-19 patients. This study not only pro-
vides a comprehensive assessment of the clinical spectrum 
of COVID-19 patients admitted to our specific urban set-
ting but also highlights the factors associated with 
increased risk of mortality amongst our cohort. We found 
that the in-hospital mortality was lower compared to the 
average mortality reported in Africa. More importantly, 
age, obesity, severe form of the disease and admission to 
ICU and HDU were factors strongly associated with 
increased risk of mortality.
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